Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322751 · ClinicalTrials.gov registry record · Phase 1
Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00322751 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 10 participants.
The verdict
NCT00322751, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Given the activity of single-agent Topotecan in NSCLC, there is both scientific rationale and a medical interest in studying this agent in combination with radiation. In addition, Topotecan administered on a weekly basis offers advantages over the daily x 5 regimen, i.e., the convenience of administration and fewer visits to the clinic.
Interventions
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322751
The ClinicalTrials.gov registry entry for NCT00322751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topotecan is the first listed.
NCT00322751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322751 about?
NCT00322751 is a clinical study titled "Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer". Given the activity of single-agent Topotecan in NSCLC, there is both scientific rationale and a medical interest in studying this agent in combination with radiation. In addition, Topotecan administered on a weekly basis offers advantages over the daily x 5 regimen, i.e., the convenience of administ...
What is the current status of trial NCT00322751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2006-04. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00322751?
The interventions under investigation include: Topotecan (DRUG).
Who is sponsoring clinical trial NCT00322751?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.